Clinical Trials in Pancreas Cancer

Clinical trials are research studies that provide hope for patients with cancer. These trials give patients access to new treatment therapies including new drugs or new ways to use existing drugs. They also include new radiation therapies, new surgical procedures, and new ways to combine different cancer treatments. The ultimate goal of each clinical trial is to find new and improved ways to safely and effectively treat cancer. Clinical trials are important to patients because they give access to treatment that would not be provided otherwise. In addition, they are important because they help get drugs approved and more easily accessible for future patients. If you are interested in learning more about the Pancreas SPORE clinical trials, you should ask your doctor or nurse if a clinical trial is available and appropriate for you.

Below are current clinical trials the Pancreas SPORE investigators are researching.

Neoadjuvant:
1. NCT02562716 - A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Adjuvant:
1. NCT01013649 - A Phase III Trial Evaluating both Erlotinib And Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma  


Borderline Resectable and Locally Advanced:
1. NCT02283372 - Prospective Phase I Study of nab-Paclitaxel plus Gemcitabine with Concurrent MR-Guided IMRT in Patients with Locally Advanced Pancreatic Cancer


Front Line:
1. NCT02608229 - Phase Ib study of BVD-523 plus nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer
2. NCT02077881 - A Phase 1/2 Study of Indoximod in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
3. NCT02651727 - A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination with Nab-paclitaxel and Gemcitabine in Subjects with Advanced Cancer 


Maintenance Therapy:
1. NCT02184195 - A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
2. NCT01896869 - A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer


Second Line:
1. NCT01834235 - A Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX
2. NCT02352831 - Phase I/II Study Combining Tosedostat with Capecitabine in Patients with Advanced or Metastatic Pancreatic Adenocarcinoma
3. NCT02501902 - An Open-Label Phase IB Study of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Abraxane (Nab-Paclitaxel) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
4. NCT02546531 - Phase I Study of Defactinib Combined with Pembrolizumab and Gemcitabine in Patients with Advanced Cancer


Any Line:
1. NCT01677559 - Phase I Study Combining MLN8237 with nab-Paclitaxel in Patients with Advanced Solid Malignancies
2. NCT02503774 - A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with durvalumab in Adult Subjects with Select Advanced Solid Tumors
3. 
NCT02546531 - Phase I Study of Defactinib Combined with Pembrolizumab and Gemcitabine in Patients with Advanced Cancer


Other:
1. NCT02028377 - Evaluation of the Novel Imaging Modality Simultaneous Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) in Patients with Pancreatic Adenocarcinoma